Harrow Launches BYOOVIZ Biosimilar, Expanding Retina Portfolio

What happened

Harrow has announced the commercial launch of BYOOVIZ, an interchangeable ranibizumab biosimilar, in the United States. This adds to its growing retina portfolio, which already includes other biosimilars like BYQLOVI. While the launch is a positive step in executing its branded growth strategy, it does little to alter the fundamental challenges of high leverage (net debt/EBITDA ~8x, interest coverage ~0.6x), persistent net losses, and regulatory overhang. The launch was already anticipated in the DeepValue master report, and the company's ability to convert such product launches into durable free cash flow remains unproven. The stock's elevated valuation already embeds expectations for successful commercialization, leaving little margin of safety.

Implication

Investors should view the launch as a necessary but insufficient step toward validating Harrow's business model. Sustained revenue growth from BYOOVIZ and other brands must translate into positive net income and free cash flow to justify the current valuation. Without clear evidence of deleveraging and operating leverage, the risk/reward remains skewed to the downside, given the stretched balance sheet and narrow moat.

Thesis delta

The BYOOVIZ launch is an expected catalyst with limited impact on the core thesis. No material shift: the sell rating is maintained due to persistent leverage, net losses, and execution risk, though the launch modestly strengthens the product pipeline.